Vaxart 경영진

경영진 기준 점검 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Steven Lo

최고경영자

n/a

총 보수

CEO 급여 비율	n/a
CEO 재임 기간	1yr
CEO 지분 보유율	n/a
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	3.6yrs

최근 경영진 업데이트

Recent updates

CEO

Steven Lo (57 yo)

1yr

재임 기간

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...

리더십 팀

이름	직위	재임 기간	보수	지분
Sean Tucker	Senior VP & Chief Scientific Officer	15.1yrs	US$1.14m	0.18% MX$ 4.3m
James Cummings	Chief Medical Officer	3.6yrs	US$1.17m	0.071% MX$ 1.7m
Steven Lo	President	1yr	데이터 없음	데이터 없음
Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	2.3yrs	데이터 없음	0.041% MX$ 965.2k
Raymond Stapleton	Chief Technology Officer	2.6yrs	데이터 없음	데이터 없음
Edward Berg	Senior VP & General Counsel	3.1yrs	데이터 없음	0.056% MX$ 1.3m
Laurie Hastings	Senior Vice President of Human Resources	less than a year	데이터 없음	데이터 없음
Shaily Garg	Senior Vice President of Clinical Development & Project Management	5yrs	데이터 없음	데이터 없음
Rajesh Kapoor	Senior Vice President of Quality	4.2yrs	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

56.5yo

평균 나이

경험이 풍부한 관리: VXRT *의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.1 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Steven Lo	President	1yr	데이터 없음	데이터 없음
Harry Greenberg	Member of Scientific & Clinical Advisory Board	3.6yrs	데이터 없음	데이터 없음
Elaine Heron	Independent Director	2.6yrs	US$89.08k	0.011% MX$ 256.6k
Michael Finney	Independent Chairman of the Board	7.1yrs	US$109.57k	0.29% MX$ 7.0m
Stanley Plotkin	Member of Scientific & Clinical Advisory Board	3.6yrs	데이터 없음	데이터 없음
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	3.6yrs	데이터 없음	데이터 없음
David Wheadon	Independent Director	3.9yrs	US$93.72k	0.0065% MX$ 153.9k
Robert Belshe	Member of Scientific & Clinical Advisory Board	3.6yrs	데이터 없음	데이터 없음
William Watson	Independent Director	2.6yrs	US$94.76k	0.023% MX$ 546.2k
Marion Pepper	Member of Scientific & Clinical Advisory Board	3.6yrs	데이터 없음	데이터 없음
Ralph Baric	Member of Scientific & Clinical Advisory Board	3.6yrs	데이터 없음	데이터 없음
Gregory Gray	Member of Scientific & Clinical Advisory Board	3.6yrs	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

69.5yo

평균 나이

경험이 풍부한 이사회: VXRT *의 이사회는 경험이 있음으로 간주됩니다(평균 재임 3.6 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/03/22 16:05
종가	2024/12/23 00:00
수익	2024/12/31
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Vaxart, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Mayank Mamtani	B. Riley Securities, Inc.
Roger Song	Jefferies LLC
null null	Oppenheimer & Co. Inc.

Vaxart 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

Vaxart, Inc., Annual General Meeting, Jul 16, 2026

Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

Vaxart, Inc. Announces Board and Committee Changes

Independent Director recently bought Mex$250k worth of stock

Recent updates

Vaxart, Inc., Annual General Meeting, Jul 16, 2026

Vaxart, Inc. to Report Q1, 2026 Results on May 07, 2026

Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Vaxart, Inc. Publishes Positive Data for Its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Vaxart, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Vaxart Receives a Letter from the Office of the General Counsel of Nasdaq

Richard John Burgess Responds to Vaxart’s Governance Announcements

Vaxart, Inc. Reports Additional Phase 1 Data Supporting the Potential Efficacy of Its Second-Generation Norovirus Oral Vaccine Candidate

Richard John Burgess Files an Exempt Solicitation Statement with Vaxart

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Richard John Burgess Urges Vaxart’s Shareholders to Vote Against Reverse Stock Split

Richard John Burgess Oppose Vaxart’s Latest Reverse Stock Split

Vaxart, Inc. to Report Q2, 2025 Results on Aug 13, 2025

Vaxart, Inc.(NasdaqCM:VXRT) dropped from S&P Global BMI Index

Vaxart, Inc.(NasdaqCM:VXRT) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Vaxart Common Stock, Suspends Trading Effective July 08

Vaxart, Inc. Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart, Inc. Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial

Vaxart, Inc. to Report Q1, 2025 Results on May 13, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Vaxart, Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025

Vaxart, Inc. Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart, Inc. Enters into Modification No. 5 (The “Modification”) to the ATI-RRPV Project Award Agreement

Vaxart, Inc. Announces Board and Committee Changes

Vaxart Highlights Progress of Covid-19, Norovirus and Influenza Programs

Vaxart Announces Favorable Dsmb Review of Sentinel Cohort from Covid-19 Phase 2B Clinical Trial

Vaxart, Inc. Provides Nasdaq Bid Price Non-Compliance Update

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Second quarter 2024 earnings released: US$0.089 loss per share (vs US$0.16 loss in 2Q 2023)

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Independent Director recently bought Mex$250k worth of stock

High number of new and inexperienced directors

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.19 loss in 1Q 2023)

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

High number of new and inexperienced directors

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Less than half of directors are independent

Less than half of directors are independent

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

High number of new and inexperienced directors

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

High number of new and inexperienced directors

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

High number of new and inexperienced directors

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors